Arrowhead Pharmaceuticals(US:ARWR) Zhi Tong Cai Jing·2026-01-12 04:43Core Viewpoint - Arrowhead Pharmaceuticals, Inc. (ARWR.US) is projected to be one of the best-performing stocks in the U.S. market by 2025, with a cumulative increase of 253%, significantly outperforming major competitors like NVIDIA (NVDA.US) and Micron (MU.US) [1][2] Group 1: Company Overview - Arrowhead Pharmaceuticals is a biotechnology company based in Pasadena, California, focusing on developing therapies for major diseases using RNA interference (RNAi) technology [3] - The company has transitioned from being a clinical-stage biotech firm to a commercialized entity with the approval of its first drug, Redemplo, marking a significant milestone in its development [5][6] Group 2: Product Details - Redemplo is an innovative RNAi-based drug approved by the FDA for treating familial chylomicronemia syndrome (FCS), representing a first-in-class therapy in its category [4][5] - The drug targets the APOC3 gene to significantly lower triglyceride levels in patients, addressing a rare genetic metabolic disorder [4] Group 3: Market Potential and Financial Projections - Piper Sandler has set a bullish target price of $100 for Arrowhead Pharmaceuticals, indicating a potential short- to mid-term upside of 55% from its current price of $64.56 [1][2] - Sales projections for Redemplo in the U.S. market are expected to reach at least $625,000 by Q4 2025, with significant growth anticipated to approximately $12.3 million by 2026 [6] - Morgan Stanley has also raised its target price for Arrowhead from $48 to $81, highlighting the potential for Redemplo to generate over $2 billion in peak global sales if successfully commercialized in broader lipid disorders [7]